Open Nav

Codagenix, Inc.

  • J. Robert Coleman, Codagenix, Inc.

Find additional Investors to join Series B syndicate

  • Date:Thursday, October 18
  • Time:9:30 AM - 9:45 AM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Codagenix, is a clinical stage, venture and public sector funded synthetic biology company utilizing rational viral design to construct designer vaccines as well as potent and targeted oncolytic viruses. To date we have raised $14M and have an established partnership in the agricultural vaccine space. For our vaccines pipeline we recently completed a Phase I/II clinical trial with our Universal Influenza Vaccine demonstrating safety similar to placebo and induction of broad, multi-decade immunity. We also plan to be in the clinic with our RSV vaccine in 2019. For oncolytics we have rationally designed a potent viral immun-oncology therapy with demonstration of preclinical efficacy. We are planning to raise a Series B ($17M) in Q1-19 to support our Universal Flu Phase II, our RSV Phase I, and potential a Phase I with our oncolytic virus. We already have commitments to join the B from Euclidean Capital and a Large Pharma VC; thus, we are seeking additional syndicate members.
  • Company
  • Company HQ City:Farmingdale NY
  • Company HQ Country:United States
  • Company HQ State:New York                    
  • CEO/Top Company Official:J. Robert Coleman
  • Year Founded:2012
  • Main Therapeutic Focus:Infectious Diseases
  • Lead Product in Development :Universal Influenza Vaccine
  • Development Phase of Primary Product:Phase I
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :3
  • Additional Information/Comments:Was invited to submit application
  • Previous and Current Investors:TopSpin Partners, NIH, USDA, US Army
  • Size of Last Investment Round:$2M
  • Total Amount Raised to Date, In All Rounds:$14M
J. Robert Coleman
Codagenix, Inc.